Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2018

Open Access 01-12-2018 | Research

Is the EQ-5D fit for purpose in asthma? Acceptability and content validity from the patient perspective

Authors: Diane Whalley, Gary Globe, Rebecca Crawford, Lynda Doward, Eskinder Tafesse, John Brazier, David Price

Published in: Health and Quality of Life Outcomes | Issue 1/2018

Login to get access

Abstract

Background

The increasing emphasis on patient-reported outcomes in health care decision making has prompted greater rigor in the evidence to support the instruments used. Acceptability and content validity are important properties of any measure to ensure it assesses the relevant aspects of the target concept. The purpose of this study was to evaluate the acceptability and content validity of the EQ-5D 5-Level (EQ-5D-5L) to assess the impact of asthma on patients’ lives.

Methods

Qualitative interviews were conducted with 40 adults with asthma in the United Kingdom. The first 25 interviews used cognitive-debriefing methods to assess the relevance and acceptability of the EQ-5D-5L and two asthma-specific measures for comparison: an asthma-specific, preference-based measure (the Asthma Quality of Life Utility Index–5 Dimensions) and an Asthma Symptom Diary. The final 15 interviews combined concept elicitation to identify patient-perceived asthma impact, and cognitive debriefing to assess relevance and acceptability of the EQ-5D-5L and the Asthma Symptom Diary. Cognitive-debriefing feedback on the content of the measures was collated and summarized descriptively. The concept-elicitation data were analyzed thematically.

Results

Participants were aged 20 to 57 years and 62.5% were female. Although some participants expressed positive opinions on aspects of the EQ-5D-5L, only the usual activities dimension was consistently considered relevant to participants’ asthma experiences. The mobility and self-care dimensions prompted strong negative reactions from some participants. Variations in interpretation of the mobility dimension and difficulties with multiple concepts in the pain/discomfort and anxiety/depression dimensions also were noted. Concepts reported by participants as missing included environmental triggers, asthma symptoms, emotions, and sleep. The EQ-5D-5L was the least preferred measure to describe the impact of asthma on participants’ lives. Participants reported shortness of breath and impact on activities as especially salient issues.

Conclusions

The content of the EQ-5D-5L was poorly aligned with the patient-perceived impact of asthma, and the measure failed to meet basic standards for acceptability and content validity as a measure to assess the impact of asthma from the patient perspective. The shortcomings identified raise concerns regarding the appropriateness of the EQ-5D in asthma and further evaluation is warranted.
Literature
1.
go back to reference Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5–21.CrossRefPubMed Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5–21.CrossRefPubMed
2.
go back to reference The EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199–208.CrossRef The EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199–208.CrossRef
3.
go back to reference Lamers LM, Bouwmans CA, van Straten A, Donker MC, Hakkaart L. Comparison of EQ-5D and SF-6D utilities in mental health patients. Health Econ. 2006 Nov;15(11):1229–36.CrossRefPubMed Lamers LM, Bouwmans CA, van Straten A, Donker MC, Hakkaart L. Comparison of EQ-5D and SF-6D utilities in mental health patients. Health Econ. 2006 Nov;15(11):1229–36.CrossRefPubMed
4.
go back to reference Devlin N, Parkin D, Browne J. Patient-reported outcome measures in the NHS: new methods for analyzing and reporting EQ-5D data. Health Econ. 2010;19:886–905.CrossRefPubMed Devlin N, Parkin D, Browne J. Patient-reported outcome measures in the NHS: new methods for analyzing and reporting EQ-5D data. Health Econ. 2010;19:886–905.CrossRefPubMed
6.
go back to reference Pizzi LT. The Institute for Clinical and Economic Review and its growing influence on the US healthcare. Am Health Drug Benefits. 2016;9(1):9–10.PubMedPubMedCentral Pizzi LT. The Institute for Clinical and Economic Review and its growing influence on the US healthcare. Am Health Drug Benefits. 2016;9(1):9–10.PubMedPubMedCentral
7.
go back to reference Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20(10):1727–1736. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20(10):1727–1736.
9.
go back to reference Janssen MF, Bonsel GJ, Luo N. Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries. PharmacoEconomics. 2018 Jun;36(6):675–97.CrossRefPubMedPubMedCentral Janssen MF, Bonsel GJ, Luo N. Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries. PharmacoEconomics. 2018 Jun;36(6):675–97.CrossRefPubMedPubMedCentral
10.
go back to reference Mulhern B, Feng Y, Shah K, Janssen MF, Herdman M, van Hout B, Devlin N. Comparing the UK EQ-5D-3L and English EQ-5D-5L value sets. PharmacoEconomics. 2018 Jun;36(6):699–713.CrossRefPubMedPubMedCentral Mulhern B, Feng Y, Shah K, Janssen MF, Herdman M, van Hout B, Devlin N. Comparing the UK EQ-5D-3L and English EQ-5D-5L value sets. PharmacoEconomics. 2018 Jun;36(6):699–713.CrossRefPubMedPubMedCentral
12.
go back to reference Young TA, Yang Y, Brazier JE, Tsuchiya A. The use of Rasch analysis in reducing a large condition-specific instrument for preference valuation: the case of moving from AQLQ to AQL-5D. Med Decis Mak. 2011;31(1):195–210.CrossRef Young TA, Yang Y, Brazier JE, Tsuchiya A. The use of Rasch analysis in reducing a large condition-specific instrument for preference valuation: the case of moving from AQLQ to AQL-5D. Med Decis Mak. 2011;31(1):195–210.CrossRef
13.
go back to reference Yang Y, Brazier J, Tsuchiya A, Young TA. Estimating a preference-based index for a 5-dimensional health state classification for asthma (AQL-5D) derived from the asthma quality of life questionnaire (AQLQ). Med Decis Mak. 2011;31(2):281–91.CrossRef Yang Y, Brazier J, Tsuchiya A, Young TA. Estimating a preference-based index for a 5-dimensional health state classification for asthma (AQL-5D) derived from the asthma quality of life questionnaire (AQLQ). Med Decis Mak. 2011;31(2):281–91.CrossRef
14.
go back to reference Rowen D, Brazier J, Young T, Gaugris S, Craig BM, King MT, Velikova G. Deriving a preference-based measure for cancer using the EORTC QLQ-C30. Value Health. 2011;14(5):721–31.CrossRefPubMed Rowen D, Brazier J, Young T, Gaugris S, Craig BM, King MT, Velikova G. Deriving a preference-based measure for cancer using the EORTC QLQ-C30. Value Health. 2011;14(5):721–31.CrossRefPubMed
15.
go back to reference Mulhern B, Rowen D, Jacoby A, Marson T, Snape D, Hughes D, et al. The development of a QALY measure for epilepsy: NEWQOL-6D. Epilepsy Behav 2012;24(1):36–43. Mulhern B, Rowen D, Jacoby A, Marson T, Snape D, Hughes D, et al. The development of a QALY measure for epilepsy: NEWQOL-6D. Epilepsy Behav 2012;24(1):36–43.
16.
go back to reference Lorgelly PK, Doble B, Rowen D, Brazier J, Cancer 2015 investigators. Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L. Qual Life Res. 2017;26(5):1163–76.CrossRefPubMed Lorgelly PK, Doble B, Rowen D, Brazier J, Cancer 2015 investigators. Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L. Qual Life Res. 2017;26(5):1163–76.CrossRefPubMed
17.
go back to reference McTaggart-Cowan HM, Marra CA, Yang Y, Brazier JE, Kopec JA, FitzGerald JM, et al. The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status. Qual Life Res. 2008;17(3):453–62.CrossRefPubMed McTaggart-Cowan HM, Marra CA, Yang Y, Brazier JE, Kopec JA, FitzGerald JM, et al. The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status. Qual Life Res. 2008;17(3):453–62.CrossRefPubMed
18.
go back to reference Mulhern B, Pink J, Rowen D, Borghs S, Butt T, Hughes D, Marson A, Brazier J. Comparing generic and condition-specific preference-based measures in epilepsy: EQ-5D-3L and NEWQOL-6D. Value Health. 2017;20(4):687–93.CrossRefPubMed Mulhern B, Pink J, Rowen D, Borghs S, Butt T, Hughes D, Marson A, Brazier J. Comparing generic and condition-specific preference-based measures in epilepsy: EQ-5D-3L and NEWQOL-6D. Value Health. 2017;20(4):687–93.CrossRefPubMed
19.
go back to reference Versteegh MM, Leunis A, Uyl-de Groot CA, Stolk EA. Condition-specific preference-based measures: benefit or burden? Value Health. 2012;15(3):504–13.CrossRefPubMed Versteegh MM, Leunis A, Uyl-de Groot CA, Stolk EA. Condition-specific preference-based measures: benefit or burden? Value Health. 2012;15(3):504–13.CrossRefPubMed
20.
go back to reference Brazier J, Deverill M. A checklist for judging preference-based measures of health related quality of life: learning from psychometrics. Health Econ. 1999;8(1):41–51.CrossRefPubMed Brazier J, Deverill M. A checklist for judging preference-based measures of health related quality of life: learning from psychometrics. Health Econ. 1999;8(1):41–51.CrossRefPubMed
23.
go back to reference Mokkink L, Terwee C, Knol D, Stratford PW, Alonso J, Patrick DL, et al. The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. BMC Med Res Methodol. 2010;10:22.CrossRefPubMedPubMedCentral Mokkink L, Terwee C, Knol D, Stratford PW, Alonso J, Patrick DL, et al. The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. BMC Med Res Methodol. 2010;10:22.CrossRefPubMedPubMedCentral
24.
go back to reference Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60(1):34–42.CrossRefPubMed Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60(1):34–42.CrossRefPubMed
25.
go back to reference Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity—establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report, part 2—assessing respondent understanding. Value Health. 2011b;14(8):978–88.CrossRefPubMed Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity—establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report, part 2—assessing respondent understanding. Value Health. 2011b;14(8):978–88.CrossRefPubMed
26.
go back to reference Valderas JM, Alonso J. Patient reported outcome measures: a model-based classification system for research and clinical practice. Qual Life Res. 2008;17(9):1125–35.CrossRefPubMed Valderas JM, Alonso J. Patient reported outcome measures: a model-based classification system for research and clinical practice. Qual Life Res. 2008;17(9):1125–35.CrossRefPubMed
27.
go back to reference Karimi M, Brazier J. Health, health-related quality of life, and quality of life: what is the difference? PharmacoEconomics. 2016;34(7):645–9.CrossRefPubMed Karimi M, Brazier J. Health, health-related quality of life, and quality of life: what is the difference? PharmacoEconomics. 2016;34(7):645–9.CrossRefPubMed
28.
go back to reference Ferrans CE. Definitions and conceptual models of quality of life. In: Lipscomb J, Gotay CC, Snyder C, editors. Outcomes assessment in cancer. Cambridge, England: Cambridge University; 2005. p. 14–30. Ferrans CE. Definitions and conceptual models of quality of life. In: Lipscomb J, Gotay CC, Snyder C, editors. Outcomes assessment in cancer. Cambridge, England: Cambridge University; 2005. p. 14–30.
29.
go back to reference Bansback N, Sun H, Guh DP, Li X, Nosyk B, Griffin S, et al. Impact of the recall period on measuring health utilities for acute events. Health Econ 2008;17(12):1413–1419. Bansback N, Sun H, Guh DP, Li X, Nosyk B, Griffin S, et al. Impact of the recall period on measuring health utilities for acute events. Health Econ 2008;17(12):1413–1419.
31.
go back to reference Matza LS, Boye KS, Stewart KD, Curtis BH, Reaney M, Landrian AS. A qualitative examination of the content validity of the EQ-5D-5L in patients with type 2 diabetes. Health Qual Life Outcomes. 2015;13(1):192.CrossRefPubMedPubMedCentral Matza LS, Boye KS, Stewart KD, Curtis BH, Reaney M, Landrian AS. A qualitative examination of the content validity of the EQ-5D-5L in patients with type 2 diabetes. Health Qual Life Outcomes. 2015;13(1):192.CrossRefPubMedPubMedCentral
32.
go back to reference van Leeuwen KM, Jansen AP, Muntinga ME, Bosmans JE, Westerman MJ, van Tulder MW, et al. Exploration of the content validity and feasibility of the EQ-5D-3L, ICECAP-O and ASCOT in older adults. BMC Health Serv Res. 2015;15:201.CrossRefPubMedPubMedCentral van Leeuwen KM, Jansen AP, Muntinga ME, Bosmans JE, Westerman MJ, van Tulder MW, et al. Exploration of the content validity and feasibility of the EQ-5D-3L, ICECAP-O and ASCOT in older adults. BMC Health Serv Res. 2015;15:201.CrossRefPubMedPubMedCentral
33.
go back to reference Globe G, Martin M, Schatz M, Wiklund I, Lin J, van Maltzahn R, et al. Symptoms and markers of symptom severity in asthma―content validity of the asthma symptom diary. Health Qual Life Outcomes. 2015;13(13):21.CrossRefPubMedPubMedCentral Globe G, Martin M, Schatz M, Wiklund I, Lin J, van Maltzahn R, et al. Symptoms and markers of symptom severity in asthma―content validity of the asthma symptom diary. Health Qual Life Outcomes. 2015;13(13):21.CrossRefPubMedPubMedCentral
34.
go back to reference Globe G, Wiklund I, Lin J, Chen WH, Martin M, Mattera MS, et al. Psychometric properties of the asthma symptom diary (ASD), a diary for use in clinical trials of persistent asthma. J Allergy Clin Immunol Pract. 2016;4(1):60–6.CrossRefPubMed Globe G, Wiklund I, Lin J, Chen WH, Martin M, Mattera MS, et al. Psychometric properties of the asthma symptom diary (ASD), a diary for use in clinical trials of persistent asthma. J Allergy Clin Immunol Pract. 2016;4(1):60–6.CrossRefPubMed
35.
go back to reference Fitzpatrick R, Davey C, Buxton MJ, Jones DR. Evaluating patient-based outcome measures for use in clinical trials Health Technol Assess 1998;2(14):i-iv, 1–74. Fitzpatrick R, Davey C, Buxton MJ, Jones DR. Evaluating patient-based outcome measures for use in clinical trials Health Technol Assess 1998;2(14):i-iv, 1–74.
36.
go back to reference Patrick DL, Burke LB, Gwaltney CJ, Leidy N, Martin ML, Molsen E, et al. Content validity―establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1―eliciting concepts for a new PRO instrument. Value Health. 2011a;14(8):967–77.CrossRefPubMed Patrick DL, Burke LB, Gwaltney CJ, Leidy N, Martin ML, Molsen E, et al. Content validity―establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1―eliciting concepts for a new PRO instrument. Value Health. 2011a;14(8):967–77.CrossRefPubMed
37.
go back to reference Revicki DA, Leidy NK, Brennan-Diember F, Sorenson S, Togias A. Integrating patient preferences into health outcomes assessment: the multiattribute asthma symptom utility index. Chest. 1998;114:998–1007.CrossRefPubMed Revicki DA, Leidy NK, Brennan-Diember F, Sorenson S, Togias A. Integrating patient preferences into health outcomes assessment: the multiattribute asthma symptom utility index. Chest. 1998;114:998–1007.CrossRefPubMed
38.
go back to reference Brédart A, Marrel A, Abetz-Webb L, Lasch K, Acquadro C. Interviewing to develop patient-reported outcome (PRO) measures for clinical research: eliciting patients' experience. Health Qual Life Outcomes. 2014;12:15.CrossRefPubMedPubMedCentral Brédart A, Marrel A, Abetz-Webb L, Lasch K, Acquadro C. Interviewing to develop patient-reported outcome (PRO) measures for clinical research: eliciting patients' experience. Health Qual Life Outcomes. 2014;12:15.CrossRefPubMedPubMedCentral
39.
40.
go back to reference Perneger TV, Courvoisier DS, Hudelson PM, Gayet-Ageron A. Sample size for pre-tests of questionnaires. Qual Life Res. 2015 Jan;24(1):147–51.CrossRefPubMed Perneger TV, Courvoisier DS, Hudelson PM, Gayet-Ageron A. Sample size for pre-tests of questionnaires. Qual Life Res. 2015 Jan;24(1):147–51.CrossRefPubMed
41.
go back to reference Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18(1):59–82.CrossRef Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18(1):59–82.CrossRef
43.
go back to reference Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47(2):76–83.CrossRefPubMedPubMedCentral Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47(2):76–83.CrossRefPubMedPubMedCentral
45.
go back to reference Juniper EF, Svensson K, Mörk AC, Ståhl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005;99(5):553–8.CrossRefPubMed Juniper EF, Svensson K, Mörk AC, Ståhl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005;99(5):553–8.CrossRefPubMed
46.
go back to reference Juniper EF, Bousquet J, Abetz L, Bateman ED, GOAL Committee. Identifying 'well-controlled' and 'not well-controlled' asthma using the asthma control questionnaire. Respir Med. 2006;100(4):616–21.CrossRefPubMed Juniper EF, Bousquet J, Abetz L, Bateman ED, GOAL Committee. Identifying 'well-controlled' and 'not well-controlled' asthma using the asthma control questionnaire. Respir Med. 2006;100(4):616–21.CrossRefPubMed
48.
go back to reference Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–103.CrossRefPubMed Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–103.CrossRefPubMed
49.
go back to reference Szende A, Svensson K, Ståhl E, Mészáros A, Berta GY. Psychometric and utility-based measures of health status of asthmatic patients with different disease control level. PharmacoEconomics. 2004;22(8):537–47.CrossRefPubMed Szende A, Svensson K, Ståhl E, Mészáros A, Berta GY. Psychometric and utility-based measures of health status of asthmatic patients with different disease control level. PharmacoEconomics. 2004;22(8):537–47.CrossRefPubMed
50.
go back to reference Sullivan PW, Ghushchyan VH, Campbell JD, Globe G, Bender B, Magid DJ. Measurement of utility in asthma: evidence indicating that generic instruments may miss clinically important changes. Qual Life Res. 2016;25(12):3017–26.CrossRefPubMed Sullivan PW, Ghushchyan VH, Campbell JD, Globe G, Bender B, Magid DJ. Measurement of utility in asthma: evidence indicating that generic instruments may miss clinically important changes. Qual Life Res. 2016;25(12):3017–26.CrossRefPubMed
51.
go back to reference Hoogendoorn M, Boland MR, Goossens LM, Oppe M, Stolk EA, Rutten van Molken M. Development of an EQ-5D respiratory bolt-on. Value Health. 2015;18(7):A714.CrossRefPubMed Hoogendoorn M, Boland MR, Goossens LM, Oppe M, Stolk EA, Rutten van Molken M. Development of an EQ-5D respiratory bolt-on. Value Health. 2015;18(7):A714.CrossRefPubMed
52.
go back to reference Luo N, Wang X, Ang M, Finkelstein EA, Aung T, Wong T-Y, et al. A vision "bolt-on" item could increase the discriminatory power of the EQ-5D index score. Value Health. 2015;18(8):1037–42.CrossRefPubMed Luo N, Wang X, Ang M, Finkelstein EA, Aung T, Wong T-Y, et al. A vision "bolt-on" item could increase the discriminatory power of the EQ-5D index score. Value Health. 2015;18(8):1037–42.CrossRefPubMed
53.
go back to reference Krabbe PF, Stouthard ME, Essink-Bot ML, Bonsel GJ. The effect of adding a cognitive dimension to the EuroQol multiattribute health-status classification system. J Clin Epidemiol. 1999;52:293–301.CrossRefPubMed Krabbe PF, Stouthard ME, Essink-Bot ML, Bonsel GJ. The effect of adding a cognitive dimension to the EuroQol multiattribute health-status classification system. J Clin Epidemiol. 1999;52:293–301.CrossRefPubMed
54.
go back to reference Swinburn P, Lloyd A, Boye KS, Edson-Heredia E, Bowman L, Janssen B. Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK. Value Health. 2013 Dec;16(8):1156–62.CrossRefPubMed Swinburn P, Lloyd A, Boye KS, Edson-Heredia E, Bowman L, Janssen B. Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK. Value Health. 2013 Dec;16(8):1156–62.CrossRefPubMed
55.
go back to reference Yang Y, Brazier J, Tsuchiya A. Effect of adding a sleep dimension to the EQ-5D descriptive system: a “bolt-on” experiment. Med Decis Mak. 2014;34:42–53.CrossRef Yang Y, Brazier J, Tsuchiya A. Effect of adding a sleep dimension to the EQ-5D descriptive system: a “bolt-on” experiment. Med Decis Mak. 2014;34:42–53.CrossRef
56.
go back to reference Yang Y, Rowen D, Brazier J, Tsuchiya A, Young T, Longworth L. An exploratory study to test the impact on three "bolt-on" items to the EQ-5D. Value Health. 2015;18(1):52–60.CrossRefPubMedPubMedCentral Yang Y, Rowen D, Brazier J, Tsuchiya A, Young T, Longworth L. An exploratory study to test the impact on three "bolt-on" items to the EQ-5D. Value Health. 2015;18(1):52–60.CrossRefPubMedPubMedCentral
57.
go back to reference Apfelbacher C, Weiss M, Saur J, Smith H, Loerbroks A. Patients’ views on asthma-specific quality of life questionnaires: qualitative interview study in Germany. J Asthma. 2012;49(8):875–83.CrossRefPubMed Apfelbacher C, Weiss M, Saur J, Smith H, Loerbroks A. Patients’ views on asthma-specific quality of life questionnaires: qualitative interview study in Germany. J Asthma. 2012;49(8):875–83.CrossRefPubMed
Metadata
Title
Is the EQ-5D fit for purpose in asthma? Acceptability and content validity from the patient perspective
Authors
Diane Whalley
Gary Globe
Rebecca Crawford
Lynda Doward
Eskinder Tafesse
John Brazier
David Price
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2018
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-018-0970-3

Other articles of this Issue 1/2018

Health and Quality of Life Outcomes 1/2018 Go to the issue